A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
Arlen
Philip M
PM
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute/National Institutes of Health, Bethesda, MD 20892-1750, USA. pa52s@nih.gov
Pazdur
Mary
M
Skarupa
Lisa
L
Rauckhorst
Myrna
M
Gulley
James L
JL
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019496:Cancer Vaccines / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D011212:Poxviridae / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D043823:Taxoids / Q000008:administration & dosage
D000972:Antineoplastic Agents, Phytogenic; D019496:Cancer Vaccines; D043823:Taxoids; D000077143:Docetaxel